Vaccinex, Inc. Stock News
$0.75
16.52%
Nasdaq, Sep 25, 02:19 pm EDT.
Closed.
Vaccinex, Inc. Stock News
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer's, Huntington's disease, and cancer today released financial results for the year ended December 31, 2025. The financial statements have been posted on the company website.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
